(Q36690302)

15 August 2017

1 reference

title

Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine (English)

1 reference

15 August 2017

1

Antonio Cassone

1 reference

15 August 2017

author name string

Antonella Torosantucci

series ordinal

2

1 reference

15 August 2017

publication date

1 December 2006

1 reference

Expert Review of Vaccines

15 August 2017

published in

1 reference

15 August 2017

volume

5

1 reference

15 August 2017

issue

6

1 reference

15 August 2017

page(s)

859-867

1 reference

Preventative and therapeutic vaccines for fungal infections: from concept to implementation

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Progress in vaccination for histoplasmosis and blastomycosis: coping with cellular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Induced humoral immunity and vaccination against major human fungal pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Passive antibody therapy for infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Coccidioidomycosis: host response and vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Prospects of vaccines for invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Is a vaccine needed against Candida albicans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Vaccinate against aspergillosis! A call to arms of the immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Invasive candidiasis in immunocompromised hospitalized patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Recombinant antibodies: a natural partner in combinatorial antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Hybridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Polysaccharide-containing conjugate vaccines for fungal diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Candidacidal activity of a monoclonal antibody that binds with glycosyl moieties of proteins of Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Antibodies, killer toxins and antifungal immunoprotection: a lesson from nature?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Inhibition of fungal beta-1,3-glucan synthase and cell growth by HM-1 killer toxin single-chain anti-idiotypic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

A novel glyco-conjugate vaccine against fungal pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Fungal β-Glucans and Mammalian Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Molecular organization of the cell wall of Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Contributions of hyphae and hypha-co-regulated genes to Candida albicans virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Dectin-1 mediates macrophage recognition of Candida albicans yeast but not filaments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Dendritic cell-based vaccination against opportunistic fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

21 January 2018

Engineered antibodies

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

Dendritic cells pulsed with fungal RNA induce protective immunity to Candida albicans in hematopoietic transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.6.859

21 January 2018

Identifiers

DOI

10.1586/14760584.5.6.859

1 reference

15 August 2017

1 reference